KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Free Cash Flow: 2011-2025

Historic Free Cash Flow for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$61.8 million.

  • Supernus Pharmaceuticals' Free Cash Flow fell 215.89% to -$61.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.8 million, marking a year-over-year decrease of 58.87%. This contributed to the annual value of $171.2 million for FY2024, which is 54.91% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Free Cash Flow stood at -$61.8 million, which was down 206.39% from $58.1 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Free Cash Flow's 5-year high stood at $71.4 million during Q2 2022, with a 5-year trough of -$61.8 million in Q3 2025.
  • For the 3-year period, Supernus Pharmaceuticals' Free Cash Flow averaged around $28.0 million, with its median value being $38.2 million (2024).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Free Cash Flow soared by 1,315.47% in 2023, and later tumbled by 215.89% in 2025.
  • Supernus Pharmaceuticals' Free Cash Flow (Quarterly) stood at $48.8 million in 2021, then plummeted by 43.13% to $27.7 million in 2022, then spiked by 62.25% to $45.0 million in 2023, then decreased by 1.78% to $44.2 million in 2024, then crashed by 215.89% to -$61.8 million in 2025.
  • Its last three reported values are -$61.8 million in Q3 2025, $58.1 million for Q2 2025, and $30.3 million during Q1 2025.